MedWatch

Finance analyst: Novo's sales from obesity drugs may grow earlier than anticipated

Novo Nordisk may see accelerated sales of obesity drugs sooner than expected, thinks Danish bank analyst, who sees great potential in upcoming new data for semaglutide as an obesity treatment.

Photo: Novo Nordisk / PR

Preliminary data from a crucial trial concerning a Novo Nordisk obesity drug may accelerate sales in 2023, according to Danish newspaper Børsen in reference to an analysis from Danish bank and financial analyst Nordea.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs